Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

Drug Name

Isturisa® (osilodrostat)

Developer

Novartis, Recordati

Therapy Class

Cortisol synthesis inhibitor

Product Description

11-beta-hyrdoxylase enzyme inhibitor

Current Indication

Cushing’s disease

Market Sector

Metabolic disorder

Development Status

Approved in the US and Europe.
Expand
Close
Close
Close

Go Top